NTRS
39
-3
EXPE
72
-5
TAP
66
8
CRM
35
-7
ADSK
49
-4
IP
60
-5
GOOG
57
-4
AIZ
78
3
PYPL
27
-6
M
23
-2
CL
51
4
FTI
78
12
GM
63
-8
BIIB
45
6
PPL
72
2
CTAS
45
9
PX
65
-3
WDC
37
10
MMC
70
2
MAR
38
2
NTRS
39
-3
EXPE
72
-5
TAP
66
8
CRM
35
-7
ADSK
49
-4
IP
60
-5
GOOG
57
-4
AIZ
78
3
PYPL
27
-6
M
23
-2
CL
51
4
FTI
78
12
GM
63
-8
BIIB
45
6
PPL
72
2
CTAS
45
9
PX
65
-3
WDC
37
10
MMC
70
2
MAR
38
2
Financhill
Back

Ultragenyx Pharmaceutical Stock Predictions

Meet the Founder That's Revolutionizing Smartphones

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
17

RARE
Ultragenyx Pharmaceutical

Last Price:
$38.90
Seasonality Move:
14.41%

7 Day Trial

ALL ACCESS PASS

$ 7

Why Private Investors Didn't Lose a Penny in the Market's Recent $1T Crash

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

Ultragenyx Pharmaceutical Stock Forecast

  • Over the next 52 weeks, Ultragenyx Pharmaceutical has on average historically risen by 7.3% based on the past 11 years of stock performance.
  • Ultragenyx Pharmaceutical has risen higher in 6 of those 11 years over the subsequent 52-week period, corresponding to a historical accuracy of 54.55%
  • Is Ultragenyx Pharmaceutical Stock Undervalued?
    The current Ultragenyx Pharmaceutical [RARE] share price is $37.98. The Score for RARE is 17, which is 66% below its historic median score of 50, and infers higher risk than normal.
  • RARE is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.

Will Ultragenyx Pharmaceutical Stock Go Up Next Year?

  • Over the next 52 weeks, Ultragenyx Pharmaceutical has on average historically risen by 7.3% based on the past 11 years of stock performance.

Ultragenyx Pharmaceutical Stock Rating

Sell
17
Ultragenyx Pharmaceutical (RARE) is a Sell

Is Ultragenyx Pharmaceutical overpriced?

  • Ultragenyx Pharmaceutical has risen higher in 6 of those 11 years over the subsequent 52-week period, corresponding to a historical accuracy of 54.55%

Ultragenyx Pharmaceutical Stock Price History

Is RARE stock going to rise?

  • Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and RARE is experiencing slight buying pressure.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
ultragenyx.com

52-Week Data

52-Week High:
60.37
52-Week Low:
36.71

Prediction Charts

Market Cap:
3.5B
Price in USD:
37.98
Volume:
976.7K
Beta:
1.09

Technical Analysis

SMA50:
41.81
SMA100:
44.35
SMA200:
47.07
52-Wk Change:
-16.45%

Stock Predictions

  • Is Ultragenyx Pharmaceutical stock public?
    Yes, Ultragenyx Pharmaceutical is a publicly traded company.
  • What is the Ultragenyx Pharmaceutical stock quote today?
    The Ultragenyx Pharmaceutical stock price is 37.98 USD today.
  • How to buy Ultragenyx Pharmaceutical stock online?
    You can buy Ultragenyx Pharmaceutical shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Mar-6 40.06 40.06 41.11 39.83
Mar-7 40.08 38.62 40.25 38.61
Mar-11 37.53 38.33 38.66 37.26
Mar-12 38.50 40.29 40.43 38.29
Mar-13 40.26 39.25 40.54 39.19
Mar-14 39.32 39.34 40.06 39.05
Mar-17 39.11 39.64 40.07 38.48
Mar-18 39.02 38.86 39.52 38.65
Mar-19 38.86 39.68 40.15 38.70
Mar-20 39.33 38.89 40.21 38.86
Mar-21 38.53 39.18 39.28 38.18
Mar-24 39.44 39.36 39.87 38.99
Mar-25 39.19 38.69 39.19 38.12
Mar-26 38.77 37.98 38.77 36.71

Ultragenyx Pharmaceutical Earnings

Ultragenyx Pharmaceutical Earnings Report: Per Share Ultragenyx Pharmaceutical Earnings Q1 Q2 Q3 and Q4 last year and next year.

Ultragenyx Pharmaceutical Forecast Revenue Growth

Ultragenyx Pharmaceutical Stock Analysis: Historical quarterly revenues per share for Ultragenyx Pharmaceutical and historical quarterly revenue growth:

  • Analysts estimate an earnings increase this quarter of $0.15 per share, a decrease next quarter of $0.03 per share, an increase this year of $0.74 per share, and an increase next year of $1.83 per share.

* Ultragenyx Pharmaceutical stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.